DK3458085T5 - Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik - Google Patents

Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik Download PDF

Info

Publication number
DK3458085T5
DK3458085T5 DK17724760.8T DK17724760T DK3458085T5 DK 3458085 T5 DK3458085 T5 DK 3458085T5 DK 17724760 T DK17724760 T DK 17724760T DK 3458085 T5 DK3458085 T5 DK 3458085T5
Authority
DK
Denmark
Prior art keywords
fusion proteins
enhanced pharmacokinetics
vwf fusion
glycosylated
glycosylated vwf
Prior art date
Application number
DK17724760.8T
Other languages
English (en)
Other versions
DK3458085T3 (da
Inventor
Christoph Kannicht
Barbara Solecka-Witulska
Tilo Schwientek
Stefan Winge
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Application granted granted Critical
Publication of DK3458085T3 publication Critical patent/DK3458085T3/da
Publication of DK3458085T5 publication Critical patent/DK3458085T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17724760.8T 2016-05-20 2017-04-26 Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik DK3458085T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170690 2016-05-20
PCT/EP2017/059976 WO2017198435A1 (en) 2016-05-20 2017-04-26 Glycosylated vwf fusion proteins with improved pharmacokinetics

Publications (2)

Publication Number Publication Date
DK3458085T3 DK3458085T3 (da) 2023-01-30
DK3458085T5 true DK3458085T5 (da) 2024-09-09

Family

ID=56101290

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17724760.8T DK3458085T5 (da) 2016-05-20 2017-04-26 Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik
DK17729037.6T DK3458080T3 (da) 2016-05-20 2017-05-22 Polypeptidmodulerende siglec-afhængige immunreaktioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17729037.6T DK3458080T3 (da) 2016-05-20 2017-05-22 Polypeptidmodulerende siglec-afhængige immunreaktioner

Country Status (12)

Country Link
US (3) US12171808B2 (da)
EP (2) EP3458085B1 (da)
JP (5) JP7626514B2 (da)
KR (4) KR20190012189A (da)
CN (3) CN109152817A (da)
AU (3) AU2017267047B2 (da)
BR (2) BR112018073669A2 (da)
CA (2) CA3024349A1 (da)
DK (2) DK3458085T5 (da)
ES (2) ES2938890T3 (da)
IL (2) IL262887B2 (da)
WO (2) WO2017198435A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458085B1 (en) * 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
EP3848388B1 (en) * 2018-09-05 2025-08-20 LG Chem, Ltd. Fusion polypeptide comprising polypeptide region that can be o-glycosylated
US20220305089A1 (en) 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf
CA3159979A1 (en) * 2019-12-11 2021-06-17 Yeonchul Kim Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
CN113899902B (zh) * 2020-06-22 2024-10-29 上海科技大学 一种酪氨酸磷酸酶底物鉴定方法
CN115896074A (zh) * 2022-12-19 2023-04-04 成都蓉生药业有限责任公司 一种人凝血因子ix纯化的亲和层析缓冲液体系及纯化方法
KR20250168493A (ko) 2023-03-31 2025-12-02 옥타파마 아게 개선된 약동학을 갖는 fviii-vwf 융합 단백질
WO2025181343A1 (en) 2024-02-29 2025-09-04 Octapharma Ag Cystine knot domain fusion protein dimers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686901A1 (fr) * 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第viii因子変異体および使用の方法
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
WO2013120939A1 (en) * 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー/エス 血友病の治療に適する化合物
CN104661674A (zh) * 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CA2910110A1 (en) 2013-04-22 2014-10-30 The Scripps Research Institute Methods and compositions for treating bleeding disorders
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
AU2015270394B2 (en) 2014-06-06 2017-12-21 Octapharma Ag Preparation comprising Factor VIII and Von Willebrand factor peptides
EP3458085B1 (en) * 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics

Also Published As

Publication number Publication date
US12171808B2 (en) 2024-12-24
JP2019522962A (ja) 2019-08-22
AU2017267047A1 (en) 2018-11-29
BR112018073669A2 (pt) 2019-02-26
KR20240126070A (ko) 2024-08-20
DK3458080T3 (da) 2024-10-14
JP7626514B2 (ja) 2025-02-07
JP2025016467A (ja) 2025-02-04
AU2017266758C1 (en) 2022-03-03
IL262887B2 (en) 2025-02-01
CN115960208A (zh) 2023-04-14
IL262887B1 (en) 2024-10-01
RU2018145062A3 (da) 2020-10-08
KR102876983B1 (ko) 2025-10-27
ES2938890T3 (es) 2023-04-17
WO2017198435A1 (en) 2017-11-23
AU2017266758B2 (en) 2021-08-05
JP2025121974A (ja) 2025-08-20
RU2018144112A (ru) 2020-06-22
EP3458080B1 (en) 2024-07-10
IL262967B1 (en) 2023-04-01
EP3458080A1 (en) 2019-03-27
CN109152809A (zh) 2019-01-04
IL262967A (en) 2018-12-31
DK3458085T3 (da) 2023-01-30
US20190201495A1 (en) 2019-07-04
EP3458085B1 (en) 2022-12-07
AU2017267047B2 (en) 2023-11-09
US20210275644A1 (en) 2021-09-09
RU2018144112A3 (da) 2021-03-10
BR112018073674A2 (pt) 2019-02-26
AU2021261911A1 (en) 2021-12-02
JP2019519220A (ja) 2019-07-11
ES2988357T3 (es) 2024-11-20
EP3458085A1 (en) 2019-03-27
IL262967B2 (en) 2023-08-01
CA3024378A1 (en) 2017-11-23
KR20190007500A (ko) 2019-01-22
IL262887A (en) 2018-12-31
JP7311970B2 (ja) 2023-07-20
US20190169268A1 (en) 2019-06-06
WO2017198877A1 (en) 2017-11-23
KR20190012189A (ko) 2019-02-08
US11013789B2 (en) 2021-05-25
JP2023134586A (ja) 2023-09-27
AU2017266758A1 (en) 2018-11-29
CA3024349A1 (en) 2017-11-23
AU2021261911B2 (en) 2023-06-29
KR20230169477A (ko) 2023-12-15
US11738069B2 (en) 2023-08-29
CN109152817A (zh) 2019-01-04
RU2018145062A (ru) 2020-06-23

Similar Documents

Publication Publication Date Title
DK3292141T3 (da) Fusionsproteiner
EP3519442A4 (en) Immunomodulatory fusion proteins
IL254165B (en) Immunomodulatory fusion proteins and uses thereof
IL262967A (en) Glycosylated vwf fusion proteins with improved pharmacokinetics
EP3188758C0 (en) SIRP ALPHA-ANTIBODY FUSION PROTEIN
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
PL3280727T3 (pl) Jednoramienne białka fuzyjne receptora typu I i typu II i ich zastosowania
SG11201708334RA (en) Anti-cancer fusion polypeptide
EP3561058A4 (en) Fusion protein including bdnf
ZA201706061B (en) Anti-cancer fusion polypeptide
IL241431A0 (en) Heterodimeric proteins
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
HRP20190434T1 (hr) Fuzijski protein
DK3107562T3 (da) P97-ids-fusionsproteiner
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
CL2016000219A1 (es) Proteinas de fusión terapéutica.
EP2992992A4 (en) CONNECTION OF DIFFERENT MATERIALS
EP3481412A4 (en) FUSION PROTEINS WITH EXTENDED SERUM HALF-VALUE
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
PL3256570T3 (pl) Przekierowany herpeswirus z fuzją glikoproteiny H
EP3738976C0 (en) IL-17A-BINDING FUSION PROTEIN
CL2016002136A1 (es) Proteinas de fusión uti
EP3383921A4 (en) NOVEL ANTIANGIOGENIC FUSION POLYPEPTIDE
EP3464384A4 (en) FUSION PRODUCT CONSTRUCT
BR112016029235A2 (pt) Polipeptídeos de fusão relacionados com ômega- hidroxilase com propriedades aprimoradas